Vaxcyte entered an agreement to sell $1.2 billion in common stock and warrants, along with $500 million in convertible notes. This capital raise is significant for a clinical-stage biotech company to fund development.
Vaxcyte entered an agreement to sell $1.2 billion in common stock and warrants, along with $500 million in convertible notes. This capital raise is significant for a clinical-stage biotech company to fund development.